Barros Érika Aparecida Felix de, Pontes-Junior José, Reis Sabrina Thalita, Lima Amanda Eunice Ramos, Souza Isida C, Salgueiro Jose Lucas, Fontes Douglas, Dellê Humberto, Coelho Rafael Ferreira, Viana Nayara Izabel, Leite Kátia Ramos Moreira, Nahas William C, Srougi Miguel
Nove de Julho University, São Paulo - Brazil.
Laboratory of Medical Investigation Urology Department, University of São Paulo Medical School, São Paulo - Brazil.
Int J Biol Markers. 2017 May 4;32(2):e248-e254. doi: 10.5301/jbm.5000242.
Some studies have reported that deletions at chromosome arm 9p occur frequently and represent a critical step in carcinogenesis of some neoplasms. Our aim was to evaluate the deletion of locus 9p21 and chromosomes 3, 7 and 17 in localized prostate cancer (PC) and correlate these alterations with prognostic factors and biochemical recurrence after surgery.
We retrospectively evaluated surgical specimens from 111 patients with localized PC who underwent radical prostatectomy. Biochemical recurrence was defined as a prostate-specific antigen (PSA) >0.2 ng/mL and the mean postoperative follow-up was 123 months. The deletions were evaluated using fluorescence in situ hybridization with centromeric and locus-specific probes in a tissue microarray containing 2 samples from each patient. We correlated the occurrence of any deletion with pathological stage, Gleason score, ISUP grade group, PSA and biochemical recurrence.
We observed a loss of any probe in only 8 patients (7.2%). The most common deletion was the loss of locus 9p21, which occurred in 6.4% of cases. Deletions of chromosomes 3, 7 and 17 were observed in 2.3%, 1.2% and 1.8% patients, respectively. There was no correlation between chromosome loss and Gleason score, ISUP, PSA or stage. Biochemical recurrence occurred in 83% cases involving 9p21 deletions. Loss of 9p21 locus was significantly associated with time to recurrence (p = 0.038).
We found low rates of deletion in chromosomes 3, 7 and 17 and 9p21 locus. We observed that 9p21 locus deletion was associated with worse prognosis in localized PC treated by radical prostatectomy.
一些研究报告称,9号染色体短臂缺失频繁出现,是某些肿瘤发生癌变的关键步骤。我们的目的是评估局限性前列腺癌(PC)中9p21位点以及3号、7号和17号染色体的缺失情况,并将这些改变与预后因素及术后生化复发情况相关联。
我们回顾性评估了111例接受根治性前列腺切除术的局限性PC患者的手术标本。生化复发定义为前列腺特异性抗原(PSA)>0.2 ng/mL,术后平均随访时间为123个月。在包含每位患者2个样本的组织芯片中,使用着丝粒和位点特异性探针通过荧光原位杂交评估缺失情况。我们将任何缺失的发生与病理分期、Gleason评分、国际泌尿病理学会(ISUP)分级组、PSA及生化复发情况相关联。
我们仅在8例患者(7.2%)中观察到任何探针的缺失。最常见的缺失是9p21位点的缺失,发生在6.4%的病例中。分别在2.3%、1.2%和1.8%的患者中观察到3号、7号和17号染色体的缺失。染色体缺失与Gleason评分、ISUP、PSA或分期之间无相关性。在涉及9p21缺失的病例中,83%发生了生化复发。9p21位点的缺失与复发时间显著相关(p = 0.038)。
我们发现3号、7号和17号染色体以及9p21位点的缺失率较低。我们观察到,在接受根治性前列腺切除术治疗的局限性PC中,9p21位点缺失与较差的预后相关。